- Home
- LYRA
as of 03-03-2026 12:56pm EST
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 5.6M | IPO Year: | 2020 |
| Target Price: | $16.00 | AVG Volume (30 days): | 68.9K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.85 | EPS Growth: | -13.49 |
| 52 Week Low/High: | $0.08 - $37.50 | Next Earning Date: | N/A |
| Revenue: | $1,534,000 | Revenue Growth: | -1.54% |
| Revenue Growth (this year): | -50.93% | Revenue Growth (next year): | -5.15% |
| P/E Ratio: | -0.08 | Index: | N/A |
| Free Cash Flow: | -72349000.0 | FCF Growth: | N/A |
AI-Powered LYRA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Lyra Therapeutics Inc. (LYRA)
Chief Financial Officer
Avg Cost/Share
$3.36
Shares
769
Total Value
$2,586.92
Owned After
518,547
SEC Form 4
President & CEO
Avg Cost/Share
$3.36
Shares
1,702
Total Value
$5,725.53
Owned After
1,096,733
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cavalier Jason | LYRA | Chief Financial Officer | Jan 6, 2026 | Sell | $3.36 | 769 | $2,586.92 | 518,547 | |
| Palasis Maria | LYRA | President & CEO | Jan 6, 2026 | Sell | $3.36 | 1,702 | $5,725.53 | 1,096,733 |
Compare LYRA vs Leading Stocks
See how LYRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LYRA Lyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.